CoChat

Antifungal Resistance: An Emerging Reality and A Global Challenge

Kontoyiannis, Dimitrios P · 2017 · The Journal of Infectious Diseases
Cited by 76

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Fungi are important causes of disease among organisms in the plant and animal kingdoms, including humans [1]. Because the use of antifungals is widespread in both agriculture and modern medicine, the prevalence of resistant fungal infections has been on the rise. The problem of growing antifungal resistance is exacerbated by a paucity of new antifungal agents in development that have unique mechanisms of action [2]. Given the increasing number of patients with chronic immunosuppressing conditions who require antifungal therapy as part of their supportive care, there is growing concern that we may be approaching not only the postantibiotic era but also the postantifungal era [3]. The emergence of fungal infections with innate or acquired resistance to modern antifungals is the focus of this Journal of Infectious Diseases supplement. In a series of 7 articles authored by notable experts in this field [4–10], we visit different aspects of this complex area. I would like to highlight some of what I find to be intriguing questions in this dynamic field. Resistance in both Candida and Aspergillus species has become a global problem since the introduction and widespread use of triazoles in early 1990s [11]. Reports of non-Candida species resistant to azoles and of multidrug-resistant Candida species, such as Candida glabrata [12] or, lately, Candida auris [13], are increasing with alarming frequency. In addition, the emergence of Aspergillus species that are resistant to triazoles is particularly concerning because azoles are the only oral treatment option for prophylaxis and long-term treatment of invasive fungal disease [3]. Iatrogenic selection of resistance for both Candida and Aspergillus in the past was typically restricted to patients who received prolonged treatment courses in the setting of poor source control or persistent severe immunosuppression [14, 15]. More recently, azole-resistant aspergillosis has been reported on 4 continents [16] and has been hypothesized to be driven by agricultural use of azoles [3]. This creates a difficult problem because of the need for complex containment strategies that involve regulating the agricultural use of fungicidal agents. Some intriguing questions have emerged in the epidemiology of fungal resistance. Why is the prevalence of azole resistance in Aspergillus so variable between hospitals in the same region or between countries? Is this an artifact of suboptimal sampling and/or detection methods? Early experience has suggested that more-intensive and more-systematic approaches to detect azole resistance in institutions often equate with a higher prevalence of azole-resistant Aspergillus strains. Alternatively, are there unique ecological niches in the environment or patterns of spread of resistance through geoclimatic factors that are yet to be understood (eg, global warming, wind activity, patterns of migration by birds to different areas, as appears to be the case for multidrug-resistant bacteria) [17]. For example, infections by the multidrug-resistant fungus Scedosporium prolificans have been geographically restricted to countries such as Australia and Spain [18], and amphotericin B–resistant Aspergillus terreus has been described mainly in isolated centers of Austria and Texas [19]. Clearly, investment in robust epidemiological studies is urgently needed to understand the relative contributions of the environment, specific antifungal drug classes and individual drugs (including their pharmacokinetic and pharmacodynamic behavior), and, importantly, risk factors pertaining to specific hosts. Importantly, not all patients with immunosuppression are similar in terms of their risk for resistant fungal infections and the type of such infections they acquire. Some examples are telling. First, patient with chronic granulomatous disease and severe inherent defects in neutrophil function very rarely develop the resistant mold infection mucormycosis, and the amphotericin B–resistant organism Aspergillus nidulans is a typical pathogen only in these patients [20]. On the other hand, patients with other defects in neutrophil function, such as those receiving high doses of corticosteroids for treatment of chronic graft versus host disease following allogeneic stem cell transplantation, develop this infection, especially if they are hyperglycemic and have been exposed to antifungal agents that lack Mucorales activity [21]. Second, infections by Candida krusei [22] or Fusarium solani rarely spread beyond patients with leukemia and those who have undergone hematopoietic stem cell transplantation. Fungal diagnostic assays, including tests to ensure the timely diagnosis of a resistant fungal infection, are one of the most urgent needs in medical mycology. Having better diagnostic tests would increase the possibility of implementing an effective antifungal stewardship program that would allow physicians to better distinguish colonization (a setting in which resistance frequently

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/infdis/jix179

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 76

Metadata

Authors
Kontoyiannis, D. P.
Venue
The Journal of Infectious Diseases
Published
2017-08-15
Volume
216
Issue
suppl_3
Pages
S431-S435
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W2750649777
Cited by
76
References
14
FWCI
4.63
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antifungal Resistance: An Emerging Reality and A Global Challenge. https://app.cochat.ai/papers/10.1093/infdis/jix179
The paper
Kontoyiannis, D. P. (2017). Antifungal Resistance: An Emerging Reality and A Global Challenge. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jix179

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.